Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR27 | Q9NS67 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | PPIA | P62937 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.51 |
| ▸ | IDH1 | O75874 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15840704 | 0.85 | ALDH1A1 (0.63) | GPR27ALDH1A1MAPTPPIAMEN1 | |
| SCHEMBL15840557 | 0.80 | MAPT (0.61) | ALDH1A1MAPTPPIAMEN1KMT2A | |
| SCHEMBL15840816 | 0.79 | PPIA (0.57) | ALDH1A1MAPTPPIAMEN1KMT2A | |
| SCHEMBL15840808 | 0.78 | ALDH1A1 (0.73) | GPR27ALDH1A1MAPTPPIAMEN1 | |
| SCHEMBL15840721 | 0.78 | PPIA (0.58) | GPR27ALDH1A1MAPTTSHRPPIA | |
| SCHEMBL24169260 | 0.78 | ALDH1A1 (0.61) | ALDH1A1MAPTTSHRMEN1KMT2A | |
| SCHEMBL15840655 | 0.77 | ALDH1A1 (0.71) | GPR27ALDH1A1MAPTPPIAMEN1 | |
| SCHEMBL15840434 | 0.76 | MAPT (0.70) | ALDH1A1MAPTPPIAMEN1KMT2A | |
| SCHEMBL15840560 | 0.76 | LMNA (0.60) | ALDH1A1MAPTPPIAMEN1KMT2A | |
| SCHEMBL15840806 | 0.74 | ALDH1A1 (0.67) | GPR27ALDH1A1MAPTPPIAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | GPR27 914/4885ALDH1A1 4348/4885MAPT 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.